ESPERION THERAPEUTICS

Esperion to Report Second Quarter 2021 Financial Results August 3, 2021

13 Jul 2021 08:00:03 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

01 Jul 2021 17:00:00 By Nasdaq GlobeNewswire

ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer

28 Jun 2021 07:59:40 By Nasdaq GlobeNewswire

Esperion to Participate in Two Upcoming Virtual Investor Conferences

24 May 2021 08:00:02 By Nasdaq GlobeNewswire

ESPERION Appoints Sheldon Koenig as President and CEO

17 May 2021 09:01:00 By Nasdaq GlobeNewswire

Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21

15 May 2021 12:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Two Upcoming Virtual Investor Conferences

06 May 2021 08:00:02 By Nasdaq GlobeNewswire

ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update

04 May 2021 16:01:01 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

28 Apr 2021 16:05:01 By Nasdaq GlobeNewswire

Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal

27 Apr 2021 08:00:00 By Nasdaq GlobeNewswire